Effect of Ubiquinol (reduced form of Coenzyme Q10) on Chronic Fatigue Syndrome (CFS) in double-blind placebo controlled study

News Release

Effect of Ubiquinol (reduced form of Coenzyme Q10) on Chronic Fatigue Syndrome (CFS) in double-blind placebo controlled study


-Collaborative research with Osaka City University-

KANEKA CORPORATION
August 06, 2013
Kaneka Corporation (headquarters: Osaka, Japan; President: Mr. Kimikazu Sugawara) confirmed the effect of the Reduced form of Coenzyme Q10 (hereafter, Ubiquinol) in improving the Chronic Fatigue Syndrome (CFS) showing long-lasting fatigue, tiredness, etc. with unknown cause. This research was conducted in collaboration with Special Appointment Prof. Yasuyoshi Watanabe, Graduate School of Medicine, Osaka City University, Osaka, Japan (President and Chairperson of the board of directors: Dr. Yoshiki Nishizawa), and Director of Center for Life Science Technologies, RIKEN, Kobe, Japan)

These results were presented at the 9th Annual Meeting of the Japanese Society of Fatigue Science held at Akita, Japan on June 7-8, 2013.

This is a double-blind placebo-controlled study. Thirty one patients were divided into two groups (Active; n=17, placebo; n=14) and were supplemented with Ubiquinol (150mg/day) or placebo capsules for 3 months. Fatigue, sleep quality and depression, oxidative stress and anti-oxidative activity and arithmetic tasks were evaluated before and after 3 months of the supplementation.

As the results, frequency of nocturnal awakening was significantly decreased and performance of arithmetic task was improved significantly after supplementation. Plasma Ubiquinol concentration was also increased significantly. Since these results were accorded well with those obtained in our open-label study previously conducted to evaluate the effect of Ubiquinol in CFS patients at daily dose of 150mg for 8 weeks, the clinical effect of Ubiquinol on CFS was confirmed.

News Release list
Page Top